The review article, “The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action and In Vivo and Ex Vivo Efficacy,” authored by ReAlta’ s CSO Dr. Neel Krishna PhD, CMO Dr. Kenji M. Cunnion MD, and Research Associate Dr. Grace Parker has been published in the prestigious peer-reviewed journal, Frontiers in Immunology.
This review details the development of the EPICC peptides and their efficacy in in vitro and ex vivo studies as well as in vivo efficacy in pre-clinical disease models. The EPICC peptides are a novel class of anti-inflammatory peptides that possess a unique dual-acting mechanism of action: inhibition of both complement and neutrophil mediated pathways (i.e., MPO activity and NET formation). This family of peptides were initially derived from the capsid protein of human astrovirus type 1 which was previously shown to inhibit the classical and lectin pathways of complement.
The full article can be accessed at Frontiers In Immunology, linked here.
Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...Read More
Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...Read More
Norfolk, VA, November 19, 2020 — Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, is...Read More